DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1013362
Title:
A Knock-in Reporter for a Novel AR-Targeted Therapy
Descriptive Note:
Technical Report,01 Mar 2015,29 Feb 2016
Corporate Author:
Georgia Regents Research Institute, Inc Augusta United States
Report Date:
2016-05-01
Pagination or Media Count:
52.0
Abstract:
Since castration resistance of prostate cancer is often caused by AR overexpression, down-regulation of AR expression using small molecules is a promising yet untested strategy to combat castration-resistant prostate cancer CRPC. The main objective of this research isto explore a possibility whether the CRISPR-Cas9 technology, an emerging genome-editing approach, could be applied to develop a reliable high-throughput drug screening platform for the identification of small-molecule AR transcriptional inhibitors to treat CRPC. We demonstrated in this report that the CRISPR-Cas9 system could indeed mediate high-efficient insertion of a selection gene into a site immediately downstream of the AR stop codon in castration-resistant C4-2 and 22Rv1 cells. Replacing the selection gene with a firefly luciferase FLuc gene led by an internal ribosomal entry site IRES through recombinase-mediated cassette exchange, we have successfully developed a C4-2-based recombinant cell line carrying FLuc in the AR gene locus and thereby bicistronically co-expressing the reporter gene with AR under the control of the endogenous AR promoter and enhancer. While the knock-in reporter is expected to faithfully reproduce chemical responses of the endogenous AR gene, we carried out a pilot screen using the NCI Diversity-set library and demonstrated that the genome-edited prostate cancer cells were useful in identifying small molecules inhibitory for AR expression.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
